Key Points
- COO Jim Wassil sold 7,395 shares at an average price of $58.88 on March 10, generating $435,417.60 and reducing his stake by 4.24% to 166,818 shares valued at about $9.82M.
- Vaxcyte reported quarterly EPS of ($1.80), missing the ($1.46) estimate, while PCVX traded near $56.56 with a market cap of $8.14B and a one‑year range of $27.66–$76.61.
- Institutional ownership is roughly 96.78% (major increases by T. Rowe Price, Adage, Polar Capital), and analysts hold a consensus "Moderate Buy" with a $94.50 price target.
Vaxcyte, Inc. (NASDAQ:PCVX - Get Free Report) CAO Elvia Cowan sold 2,500 shares of the stock in a transaction dated Wednesday, March 11th. The shares were sold at an average price of $58.59, for a total value of $146,475.00. Following the completion of the sale, the chief accounting officer owned 30,867 shares of the company's stock, valued at approximately $1,808,497.53. This trade represents a 7.49% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.
Elvia Cowan also recently made the following trade(s):
- On Tuesday, December 23rd, Elvia Cowan sold 11,623 shares of Vaxcyte stock. The shares were sold at an average price of $47.92, for a total transaction of $556,974.16.
Vaxcyte Trading Down 2.0%
PCVX stock traded down $1.16 during trading on Thursday, reaching $56.38. The stock had a trading volume of 77,912 shares, compared to its average volume of 1,374,137. The firm has a fifty day moving average price of $53.72 and a 200 day moving average price of $45.55. The company has a market capitalization of $8.11 billion, a P/E ratio of -10.01 and a beta of 1.31. Vaxcyte, Inc. has a 1-year low of $27.66 and a 1-year high of $76.61.
Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its earnings results on Tuesday, February 24th. The company reported ($1.80) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.46) by ($0.34). During the same period last year, the firm earned ($1.12) earnings per share. Sell-side analysts predict that Vaxcyte, Inc. will post -4.21 EPS for the current year.
Institutional Trading of Vaxcyte
Hedge funds have recently bought and sold shares of the company. Royal Bank of Canada boosted its stake in Vaxcyte by 115.2% during the 1st quarter. Royal Bank of Canada now owns 29,471 shares of the company's stock valued at $1,113,000 after purchasing an additional 15,774 shares during the period. Cubist Systematic Strategies LLC bought a new stake in shares of Vaxcyte during the first quarter valued at approximately $219,000. Caxton Associates LLP bought a new stake in shares of Vaxcyte during the first quarter valued at approximately $226,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Vaxcyte by 8.7% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 513,998 shares of the company's stock worth $19,409,000 after buying an additional 41,034 shares during the period. Finally, Atria Investments Inc grew its holdings in Vaxcyte by 11.1% in the 2nd quarter. Atria Investments Inc now owns 6,816 shares of the company's stock worth $222,000 after buying an additional 683 shares in the last quarter. 96.78% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
A number of brokerages have recently issued reports on PCVX. Needham & Company LLC upped their target price on shares of Vaxcyte from $90.00 to $110.00 and gave the company a "buy" rating in a research note on Wednesday, January 7th. Weiss Ratings restated a "sell (d-)" rating on shares of Vaxcyte in a research note on Friday, January 9th. BTIG Research lifted their target price on Vaxcyte from $85.00 to $89.00 and gave the stock a "buy" rating in a research report on Wednesday, February 25th. Leerink Partners set a $77.00 price target on Vaxcyte and gave the company an "outperform" rating in a research report on Wednesday, November 19th. Finally, Jefferies Financial Group restated a "buy" rating on shares of Vaxcyte in a research note on Tuesday. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $94.50.
Read Our Latest Stock Analysis on Vaxcyte
Vaxcyte Company Profile
(
Get Free Report)
Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company's platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.
Vaxcyte's lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
